Gennex Laboratories Limited (BOM:531739)

India · Delayed Price · Currency is INR

12.00

+1.18 (10.91%)

At close: Aug 17, 2026

-0.99% (1Y)

Market Cap	2.63B -7.2%
Revenue (ttm)	1.78B +23.9%
Net Income	206.29M +25.2%
EPS	0.74 -5.7%
Shares Out	242.95M
PE Ratio	14.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,202,735
Open	10.77
Previous Close	10.82
Day's Range	9.51 - 12.40
52-Week Range	7.05 - 17.25
Beta	0.99
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase ... [Read more]

Industry Pharmaceutical Preparations

Founded 1985

Employees 115

Stock Exchange Bombay Stock Exchange

Ticker Symbol 531739

Full Company Profile

Financial Performance

In fiscal year 2026, Gennex Laboratories's revenue was 1.73 billion, an increase of 25.26% compared to the previous year's 1.38 billion. Earnings were 209.79 million, an increase of 15.76%.

Financial Statements